| Autor: |
Landys, Karl, Borgstrom, Stig, Andersson, Torsten, Noppa, Henry |
| Zdroj: |
Investigational New Drugs; June 1985, Vol. 3 Issue: 2 p133-137, 5p |
| Abstrakt: |
Forty-two women with measurable or evaluable advanced breast cancer who had received neither prior chemotherapy for advanced disease nor any anthracycline-containing regimen as adjuvant were entered in a phase II study of mitoxantrone (Novantrone®; dihydroxyanthracenedione). Patients were aged from 36 to 80 years, performance status was from 0 to 2. All patients had normal hematological status and normal renal and liver function tests. Cardiac scintigraphy and sonography techniques were used to monitor cardiac function. Mitoxantrone was administered at a dose of 14 mg/m2 in 100 ml 5% dextrose solution over 30 minutes, repeated every three weeks. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full text from SpringerLink